Vitalis
Private Company
Funding information not available
Overview
Vitalis Therapeutics is a private, pre-revenue biotech company founded in 2019, developing VS-1, an oral ketamine solution for acute post-operative pain. The company is preparing for a Phase 2a clinical trial in total knee replacement patients, aiming to provide a non-opioid option that reduces addiction risk and side effects while potentially accelerating recovery. Led by physician-researchers, Vitalis leverages regulatory agility and aims to address a significant unmet need within the context of the opioid crisis, targeting a large and growing surgical market.
Technology Platform
Proprietary oral formulation platform for ketamine, aimed at enabling effective systemic delivery for acute analgesia as a non-opioid alternative.
Opportunities
Risk Factors
Competitive Landscape
The non-opioid acute pain space is competitive, with companies investigating various mechanisms including NaV1.8 inhibitors, novel NSAIDs, and nerve growth factor (NGF) antibodies. Vitalis's oral ketamine approach competes with other ketamine formulations (IV, nasal, sublingual) and must differentiate itself on convenience, efficacy, and side-effect profile.